RenaissanceRe Holdings enters its Q1 2026 earnings call on April 29 with the Street more divided than its calm options market suggests.
The most notable feature of positioning heading into this print is how little fear the lending market reflects. Borrow availability is extremely loose — shares available to borrow far exceed those already shorted, and the cost to borrow runs at just 0.54% annually. Short interest itself is only 2.3% of the free float, though that figure has crept up roughly 9% over the past week to around 1.06 million shares, and is 14% higher than a month ago. The climb is steady rather than aggressive, and the ORTEX short score of 33 — in the bottom half of the universe — underscores that bears are not crowding this name. Options confirm the same mood: the put/call ratio of 0.35 is only modestly above its 20-day average of 0.33. With a z-score of just 1.0, there's no meaningful rush for downside protection. The stock has gained 6.3% over the past month to close at $310.61 on April 28, even as it drifted flat on the week.
Analyst opinions heading into the print are where the tension lives. The consensus mean price target of $326.80 sits close to the current price — roughly 5% upside — but that headline figure masks sharp disagreement. BofA's Joshua Shanker maintained a Buy rating while cutting his target from $473 to $426 on April 14. That move stands out: he is bullish on the fundamental story but trimming his valuation anchor meaningfully. At the other end, Cantor Fitzgerald upgraded to Overweight on April 9 and raised to $340, while Wells Fargo held Equal-Weight and nudged its target marginally lower to $305. The bull case centres on catastrophe premium growth — particularly 13% U.S. growth in what management has called the company's highest-return business — with core loss ratios expected to improve year-over-year. The bear case is pricing: softening reinsurance rates, EPS sensitivity, and questions about whether the capital cycle can sustain current returns. Morgan Stanley downgraded to Equal-Weight in late February, and most mid-tier firms cluster around market-perform with targets near or just above current levels, suggesting the Street sees limited re-rating potential even on a clean quarter.
Institutional ownership is stable and concentrated. Vanguard holds nearly 11% of shares, BlackRock another 9.6%, and Capital Research added over 55,000 shares last quarter. Boston Partners built a position by nearly 200,000 shares in Q1. The insider picture leans the other way: the CEO, CFO, and two senior executives all sold on March 10, with CEO Kevin O'Donnell alone selling $2.3 million of stock at $297. Combined with February sales, net insider activity over the trailing 90 days reflects around $14.8 million in net selling. The trades appear routine in pattern, but the direction is worth noting: management sold into a rally.
The Q1 print is therefore less about whether RenaissanceRe's core reinsurance franchise is working — the growth in catastrophe premiums and resilient loss ratios suggest it is — and more about whether the pricing environment has deteriorated enough to justify the gap between BofA's $426 bull target and the $305–$310 cluster of more cautious estimates.
See the live data behind this article on ORTEX.
Open RNR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
